Nautilus Biotechnolgy
NAUT
76 hedge funds and large institutions have $190M invested in Nautilus Biotechnolgy in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 22 reducing their positions, and 6 closing their positions.
1,380% more call options, than puts
Call options by funds: $74K | Put options by funds: $5K
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
33% more capital invested
Capital invested by funds: $142M → $190M (+$47.2M)
18% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 22
14.67% more ownership
Funds ownership: 36.09% → 50.76% (+15%)
1% more funds holding
Funds holding: 75 → 76 (+1)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$9.97M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$452K |
| 3 |
BlackRock
New York
|
+$443K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$309K |
| 5 |
Barclays
London,
United Kingdom
|
+$173K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
ArchPoint Investors
Coral Gables,
Florida
|
-$4.58M |
| 2 |
TM
Tikvah Management
Charlotte,
North Carolina
|
-$1.68M |
| 3 |
Corient Private Wealth
Miami,
Florida
|
-$143K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$123K |
| 5 |
CC
Clearline Capital
New York
|
-$86.4K |
NAUT Hedge Fund Activity: Q4 2023 in Review
76 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Nautilus Biotechnolgy (NAUT) for Q4 2023, worth a combined $190M — up 33% from $142M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new NAUT positions and 6 closed out — a net gain of 2 holders — while 26 added to existing stakes and 22 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $9.97M. The largest seller was ArchPoint Investors, exiting entirely with an estimated $4.58M sold.
- 76 institutional investors held Nautilus Biotechnolgy (NAUT) as of Q4 2023, up from 75 in Q3 2023.
- Funds reported $190M of Nautilus Biotechnolgy stock for Q4 2023, up 33% quarter-over-quarter.
- 8 funds opened new Nautilus Biotechnolgy positions in Q4 2023 and 6 closed out, a net change of +2 holders.
- The largest Nautilus Biotechnolgy buyer in Q4 2023 was Perceptive Advisors, an estimated $9.97M added.
- The largest Nautilus Biotechnolgy seller in Q4 2023 was ArchPoint Investors, an estimated $4.58M sold.
Based on aggregated 13F filings for Q4 2023.